1
|
Riano I, Velazquez AI, Viola L, Abuali I, Jimenez K, Abioye O, Florez N. State of Cancer Control in South America: Challenges and Advancement Strategies. Hematol Oncol Clin North Am 2024; 38:55-76. [PMID: 37353378 DOI: 10.1016/j.hoc.2023.05.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/25/2023]
Abstract
Cancer is a major public health problem in South America. The cancer mortality burden is increasing in the region due to its presentation at later stages, which is related to limited access to cancer care. This results in a noticeable inequity in provisions of cancer care including specialized screening programs, as well as cancer-related treatments such as personalized medicine, radiation therapy, palliative care, and survivorship services. Consequently, South America faces many challenges for cancer control, most of them deriving from a lack of funding and unequal distribution of resources and cancer services, affecting mostly the underserved populations in the region.
Collapse
Affiliation(s)
- Ivy Riano
- Division of Hematology and Oncology, Dartmouth Cancer Center, Geisel School of Medicine Dartmouth, One Medical Drive, Lebanon, NH 03766, USA.
| | - Ana I Velazquez
- Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. https://twitter.com/AnaVManana
| | - Lucia Viola
- Fundación Neumológica Colombiana, Centro de Tratamiento e Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), Cra. 13b #161 - 85, Bogotá, Colombia. https://twitter.com/LuciaViola9
| | - Inas Abuali
- Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA. https://twitter.com/Inas_md
| | - Kathya Jimenez
- Universidad Evangelica de El Salvador, El Salvador. https://twitter.com/KathyaJimenezMD
| | - Oyepeju Abioye
- University of the Witwatersrand, School of Public Health, Johannesburg, South Africa. https://twitter.com/AbioyeOyepeju
| | - Narjust Florez
- Dana Farber Cancer Institute, Harvard School of Medicine, 450 Brookline Avenue - DA1230, Boston, MA 02215, USA. https://twitter.com/NarjustFlorezMD
| |
Collapse
|
2
|
Riano I, Contreras-Chavez P, Pabon CM, Meza K, Kiel L, Bejarano S, Florez N. An Overview of Cervical Cancer Prevention and Control in Latin America and the Caribbean Countries. Hematol Oncol Clin North Am 2024; 38:13-33. [PMID: 37330343 DOI: 10.1016/j.hoc.2023.05.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/19/2023]
Abstract
Cervical cancer is a health crisis affecting women and their families across the world. It is known that developed countries have comprehensive protocols with recommendations regarding workforce, expertise, and medical resources to address this common cancer among women. In contrast, disparities in addressing cervical cancer remain present in Latin America and Caribbean countries. Here, we reviewed the current strategies of cervical cancer prevention and control in the region.
Collapse
Affiliation(s)
- Ivy Riano
- Division of Hematology and Oncology, Dartmouth Cancer Center, Geisel School of Medicine Dartmouth, One Medical Drive, Lebanon, NH 03766, USA.
| | - Pamela Contreras-Chavez
- Division of Hematology and Oncology, Dana Farber Cancer Institute, St. Elizabeth's Medical Center, 736 Cambridge Street, Brighton, MA 02135, USA. https://twitter.com/PamChMD
| | - Cindy Medina Pabon
- Division of Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Unit 0463, 1515 Holcombe Boulevard, FC11.3055, Houston, TX 77030, USA. https://twitter.com/cmpabon
| | - Kelly Meza
- Division of Internal Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA. https://twitter.com/KellyMezaMD
| | - Lauren Kiel
- Dana Farber Cancer Institute, Harvard School of Medicine, 450 Brookline Avenue - DA1230, Boston, MA 02215, USA
| | - Suyapa Bejarano
- Department of Radiation Oncology, Liga Contra el Cancer, San Pedro Sula, Honduras
| | - Narjust Florez
- Dana Farber Cancer Institute, Harvard School of Medicine, 450 Brookline Avenue - DA1230, Boston, MA 02215, USA. https://twitter.com/NarjustFlorezMD
| |
Collapse
|
3
|
Florez N, Kiel L, Riano I, Patel S, DeCarli K, Dhawan N, Franco I, Odai-Afotey A, Meza K, Swami N, Patel J, Sequist LV. Lung Cancer in Women: The Past, Present, and Future. Clin Lung Cancer 2024; 25:1-8. [PMID: 37940410 DOI: 10.1016/j.cllc.2023.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Revised: 09/29/2023] [Accepted: 10/18/2023] [Indexed: 11/10/2023]
Abstract
Lung cancer is the leading cause of cancer death for women in multiple countries including the United States. Women are exposed to unique risk factors that remain largely understudied such as indoor pollution, second-hand tobacco exposure, biological differences, gender differences in tolerability and response to therapy in lung cancer, and societal gender roles, that create distinct survivorship needs. Women continue to lack representation in lung cancer clinical trials and are typically treated with data generated from majority male patient study populations, which may be inappropriate to extrapolate and generalize to females. Current lung cancer treatment and screening guidelines do not incorporate sex-specific differences and physicians also often do not account for gender differences when choosing treatments or discussing survivorship needs. To best provide targeted treatment approaches, greater representation of women in lung cancer clinical trials and further research is necessary. Clinicians should understand the unique factors and consequences associated with lung cancer in women; thus, a holistic approach that acknowledges environmental and societal factors is necessary.
Collapse
Affiliation(s)
- Narjust Florez
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
| | | | - Ivy Riano
- Section of Hematology and Medical Oncology, Dartmouth Cancer Center, Geisel School of Medicine Dartmouth, Lebanon, NH
| | - Shruti Patel
- Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA
| | - Kathryn DeCarli
- Division of Hematology/Oncology, The Warren Alpert Medical School of Brown University, Providence, RI
| | - Natasha Dhawan
- Section of Hematology and Medical Oncology, Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH
| | - Ivy Franco
- Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | | | - Kelly Meza
- Dana-Farber Cancer Institute, Boston, MA
| | - Nishwant Swami
- University of Massachusetts Medical School, Worcester, MA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA
| | | | - Lecia V Sequist
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
| |
Collapse
|
4
|
Kondrashov A, Sapkota S, Sharma A, Riano I, Kurzrock R, Adashek JJ. Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload. Pharmaceutics 2023; 15:2160. [PMID: 37631374 PMCID: PMC10459723 DOI: 10.3390/pharmaceutics15082160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 08/10/2023] [Accepted: 08/16/2023] [Indexed: 08/27/2023] Open
Abstract
Antibody-drug conjugates (ADCs) are at the forefront of the drug development revolution occurring in oncology. Formed from three main components-an antibody, a linker molecule, and a cytotoxic agent ("payload"), ADCs have the unique ability to deliver cytotoxic agents to cells expressing a specific antigen, a great leap forward from traditional chemotherapeutic approaches that cause widespread effects without specificity. A variety of payloads can be used, including most frequently microtubular inhibitors (auristatins and maytansinoids), as well as topoisomerase inhibitors and alkylating agents. Finally, linkers play a critical role in the ADCs' effect, as cleavable moieties that serve as linkers impact site-specific activation as well as bystander killing effects, an upshot that is especially important in solid tumors that often express a variety of antigens. While ADCs were initially used in hematologic malignancies, their utility has been demonstrated in multiple solid tumor malignancies, including breast, gastrointestinal, lung, cervical, ovarian, and urothelial cancers. Currently, six ADCs are FDA-approved for the treatment of solid tumors: ado-trastuzumab emtansine and trastuzumab deruxtecan, both anti-HER2; enfortumab-vedotin, targeting nectin-4; sacituzuzmab govitecan, targeting Trop2; tisotumab vedotin, targeting tissue factor; and mirvetuximab soravtansine, targeting folate receptor-alpha. Although they demonstrate utility and tolerable safety profiles, ADCs may become ineffective as tumor cells undergo evolution to avoid expressing the specific antigen being targeted. Furthermore, the current cost of ADCs can be limiting their reach. Here, we review the structure and functions of ADCs, as well as ongoing clinical investigations into novel ADCs and their potential as treatments of solid malignancies.
Collapse
Affiliation(s)
- Aleksei Kondrashov
- Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD 21229, USA; (A.K.); (S.S.)
| | - Surendra Sapkota
- Department of Internal Medicine, Saint Agnes Hospital, Baltimore, MD 21229, USA; (A.K.); (S.S.)
| | - Aditya Sharma
- Department of Internal Medicine, Dartmouth Health, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA; (A.S.); (I.R.)
| | - Ivy Riano
- Department of Internal Medicine, Dartmouth Health, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA; (A.S.); (I.R.)
- Division of Hematology and Oncology, Dartmouth Cancer Center, Lebanon, NH 03755, USA
| | - Razelle Kurzrock
- WIN Consortium, 94550 Paris, France;
- MCW Cancer Center, Milwaukee, WI 53226, USA
- Division of Oncology and Hematology, University of Nebraska, Omaha, NE 68198, USA
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
| | - Jacob J. Adashek
- Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
| |
Collapse
|
5
|
Patel SR, Riano I, Abuali I, Ai A, Geiger G, Pimienta J, Ramirez Roggio A, Dhawan N, Dizman N, Lizette Salinas A, Pomares-Millan H, Florez N. Race/Ethnicity and Gender Representation in Hematology and Oncology Editorial Boards: What is the State of Diversity? Oncologist 2023:7147068. [PMID: 37119268 DOI: 10.1093/oncolo/oyad103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Accepted: 03/23/2023] [Indexed: 05/01/2023] Open
Abstract
INTRODUCTION Women and underrepresented groups in medicine hold few academic leadership positions in the field of hematology/oncology. In this study, we assessed gender and race/ethnicity representation in editorial board positions in hematology/oncology journals. MATERIALS AND METHODS Editorial leadership board members from 60 major journals in hematology and oncology were reviewed; 54 journals were included in the final analysis. Gender and race/ethnicity were determined based on publicly available data for Editor-in-Chief (EiC) and Second-in-Command (SiC) (including deputy, senior, or associate editors). Descriptive statistics and chi-squared were estimated. In the second phase of the study, editors were emailed a 4-item survey to self-identify their demographics. RESULTS Out of 793 editorial board members, 72.6% were men and 27.4% were women. Editorial leadership were non-Hispanic white (71.1%) with Asian editorial board members representing the second largest majority at 22.5%. Women comprised only 15.9% of the EiC positions (90% White and 10% Asian). Women were about half as likely to be in the EiC position compared with men [pOR 0.47 (95% CI, 0.23-0.95, P = .03)]. Women represented 28.3% of SiC editorial positions. Surgical oncology had the lowest female representation at 2.3%. CONCLUSION Women and minorities are significantly underrepresented in leadership roles on Editorial Boards in hematology/oncology journals. Importantly, the representation of minority women physicians in EiC positions is at an inexorable zero.
Collapse
Affiliation(s)
- Shruti R Patel
- Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
| | - Ivy Riano
- Division of Hematology and Oncology, Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
| | - Inas Abuali
- Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Angela Ai
- Department of Medicine, Olive View-UCLA, Sylmar, CA, USA
| | - Gabriella Geiger
- Department of Internal Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | - Jacqueline Pimienta
- Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA
| | | | - Natasha Dhawan
- Division of Hematology and Oncology, Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA
| | - Nazli Dizman
- Department of Medicine, Yale School of Medicine, New Haven, CT, USA
| | | | - Hugo Pomares-Millan
- Department of Clinical Sciences, Clinical Research Centre, Lund University, Malmö, Sweden
| | - Narjust Florez
- Department of Thoracic Oncology, Dana Farber Cancer Institute, Harvard School of Medicine, Boston, MA, USA
| |
Collapse
|
6
|
Abu Rous F, Riano I. Challenges Faced by J-1 International Medical Graduates (IMGs) During COVID-19 Pandemic. Cancer Invest 2023; 41:1-4. [PMID: 36745487 DOI: 10.1080/07357907.2023.2177859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Accepted: 01/31/2023] [Indexed: 02/07/2023]
Abstract
In March 2020, WHO declared COVID-19 a global pandemic which led to many countries closing their borders to contain the spread of the virus, stay-at-home mandates were announced and governmental entities started working on minimal capacity. Delays in visa processing and renewal is one aspect that was hugely impacted by the pandemic and led to interruption in the training of many international medical graduates (IMGs). In this manuscript, we share our stories and perspective on the challenges faced by IMGs holding J-1 visa during COVID-19 pandemic.
Collapse
Affiliation(s)
- Fawzi Abu Rous
- Division of Hematology and Oncology, Department of Internal Medicine, Henry Ford Health, Detroit, MI, USA
| | - Ivy Riano
- Unit of Hematology and Oncology, Dartmouth Cancer Center, Geisel School of Medicine Dartmouth, Lebanon, NH, USA
| |
Collapse
|
7
|
Riano I, Pomares-Millan H, Hammill CW, Trikalinos N. Evaluating the quality of clinical evidence in gastrointestinal cancers PubMed searches: How relevant are the results? J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.11037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11037 Background: Bibliographic repositories have become increasingly important as clinical evidence is more accessible on the internet. Often, oncologists rely on published literature to guide patient care. However, with the proliferation of journals and increasing number of peer reviewed papers, current search strategies have the potential to retrieve large numbers of irrelevant or misleading articles. Moreover, access to current best evidence may require paid subscriptions. Here, we assessed the quality of retrieved medical literature pertaining to treatment of gastrointestinal cancers using the PubMed database. Methods: We interrogated 6 focused-therapy questions in 3 categories: medical oncology (MedOnc), surgical oncology (SurgOnc), and alternative medicine (AltMed). We extracted journal metrics of the first two pages (40 results) from each search. We defined the composite outcome “relevant result” as the product of removing results from 1) predatory journals (Beall’s list), 2) non-English language, and 3) no free access publications. As a sensitivity analysis, we defined 2007 as a cutoff for “relevant” publications and Impact Factor (IF) > 3 or H-index > 50. Results: Two hundred and forty results were retrieved (80 per search type). Forty-eight percent of the journals were European (n = 115), 40% US-based (n = 96), and 94% were in English (n = 225). Most journals (n = 170; 70.8%) had an IF between 1-10, followed by ̃21% with an IF > 10 (n = 51); yet ̃45% (n = 107) were in the Clarivate Analytics top quartile. Sixty percent (n = 139) of articles were free to access. The articles had a median H-index of 117 [IR 59, 168]. When modelling the multivariate association with “relevant result”, year of publication after 2007 had an OR = 1.07 (95% CI = 1.01-1.14; p< 0.02) and availability through GOLD Open Access by Clarivate Analytics had an OR = 1.09 (95% CI = 1.03-1.15; p< 0.0008). MedOnc retrieved more papers published in journals with IF > 10 (n = 31; 38.8%) than SurgOnc searches (n = 12; 15%; p< 0.001). Only the AltMed searches included non-peer reviewed publications (n = 4; 5%) and 4 results were from “predatory journals”, all in MedOnc. Conclusions: Articles had a 7% higher chance of being considered a “relevant result” if they were published after 2007 and a 9% higher chance if available under GOLD Open Access. Publications identified as “relevant results” with an IF or H-index above the established cutoffs, had a 6% higher chance to be in the top 40 PubMed search results. In the sensitivity analysis the results remain virtually unchanged. Importantly, nearly 40% of papers indexed in PubMed do not have free full-text articles, making them unavailable to oncologists without access to a medical library or paid subscription. These results highlight the imperative to deliver relevant, freely accessible information that can impact the care of the cancer patients.
Collapse
Affiliation(s)
- Ivy Riano
- Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | | | - Chet W. Hammill
- Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
| | - Nikolaos Trikalinos
- Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
| |
Collapse
|
8
|
Patel SR, Riano I, Abuali I, Ai A, Geiger G, Pimienta J, Ramirez Roggio AC, Dhawan N, Salinas AL, Duma N, Dizman N. Comparison of methodology in the collection of gender and race/ethnicity in hematology and oncology journal editorial boards. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.11061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11061 Background: Reporting on disparities is strongly influenced by the methodology used to collect race/ethnicity and gender data. Incorporating gender and race into research has its challenges, as these variables are difficult to define. As underrepresentation of minorities and women continues to persist in many facets of academia, it is important to assess the accuracy of differing methodologies. While asking individuals to self-identify their race and gender remains the gold standard of reporting, low response rates and response bias have been shown to affect results. In our initial study on representation in editorial boards, gender and race/ethnicity were determined based on publicly available data which can lead to misclassification of editors. We aimed to add to our study by asking editors to self-report their gender and race in hopes to validate our methodology given the importance of considering gender and race in academia. Methods: Of the 60 highest impact journals in oncology, hematology, radiation oncology, and surgical oncology identified, race/ethnicity and gender determinations were made using two methods. All senior editors were sent a survey via email asking participants to self-report their gender, race/ethnicity, age, and job characteristics. Gender and race were also assigned to the editors by a diverse coding team based on publicly available data and the NIH's OMB Directive 15 as a framework. The self-reported data was then compared to data that was assigned by our team. Results: 66 of the 793 (8.3%) editorial board members included in the study responded to the survey. Of the 66 respondents, gender was assigned correctly 100% (66/66) of the time and race was assigned correctly 95.5% (63/66) of the time. Of the 66 respondents to the self-survey of the 793 editorial board members surveyed. A significantly lower proportion of men responded to the survey compared to the gender breakdown of the 793 editorial board members (54.5% vs 72.6%; p = 0.000279). The three incorrectly identified respondents self-identified as Native Hawaiian, White, and Middle Eastern. Conclusions: Multiple recent reports have demonstrated high rates of sexual harassment, gender bias, and exclusion in the field of oncology. Collecting data on racial/ethnic groups and gender is imperative to understand the academic landscape of oncology and work towards a more equitable environment. Notably, this data from our study supports the methodology of a diverse coding team assigning gender and race based on publicly available data and the NIH's OMB Directive 15 as a framework as an alternative to self-report. Our study also demonstrates the low response rates and significant discrepancies in the demographic of respondents seen in survey-based identification.
Collapse
Affiliation(s)
| | - Ivy Riano
- Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | | | - Angela Ai
- University of California Los Angeles - Olive View, Sylmar, CA
| | - Gabriella Geiger
- University of Wisconsin School of Medicine and Public Health, Madison, WI
| | | | | | - Natasha Dhawan
- Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | | | - Narjust Duma
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| | - Nazli Dizman
- City of Hope Comprehensive Cancer Center, Duarte, CA
| |
Collapse
|
9
|
Riano I, Patel SR, Abuali I, Ai A, Geiger G, Pimienta J, Ramirez Roggio A, Dhawan N, Dizman N, Salinas AL, Duma N. Self-identification of gender and race/ethnicity in hematology and oncology journal editorial boards: What is the state of diversity? J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.11058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11058 Background: Underrepresentation of women and minorities persists in many aspects of the scholarly publication process as demonstrated by our initial findings presented at ASCO21. Having a gender-balanced and diverse editorial team promotes collaborative work and decreases the publication bias against women. In our initial study, gender and race/ethnicity were determined based on publicly available data. We aimed to add to our study by asking editors to self-report their gender and race to assess the diversity of editors at leading hematology and oncology journals by self-reporting. Methods: We identified 60 journals in oncology, hematology, radiation oncology, and surgical oncology with the highest impact factors. Editors-In-Chief (EiC) and Second-In-Command (SiC) editors (such as deputy, senior and associated editors) were included in the analysis. A demographic survey assessing gender, race/ethnicity, age, and job characteristics was sent to 793 participants via email. Data were analyzed with R software. Results: A total of 66 out of 793 editorial board members responded to the survey. Gender breakdown of respondents was 36 (54.5%) men and 30 (45.8%) women. Most respondents were between the ages of 40 and 60 (69.7%). Thirty-eight (57.6%) of the editors had ≤5 years of editorial experience. Of the 66 respondents, 44 (66.7%) self-identified as non-Hispanic white, followed by 14 (21.2%) as Asian and 3 (4.5%) as Hispanic. Only 1/66 (1.5%) editors self-identified as Black or Native Hawaiian/Other Pacific Islander, and 1/66 (1.5%) did not identify themselves with a racial group. Conclusions: Underrepresented groups in medicine (URM) and women occupied a minority of leadership roles on editorial boards in high-impact hematology and oncology journals. Notably, this study provides new insights into editorial board diversity by using self-reporting as a primary methodology. Limitations of the cross-sectional study is that URM and women are more likely to respond to surveys on diversity, equity, and inclusion potentially skewing the results. Diversity in editorial boards not only can enhance scientific discovery by encouraging submissions from researchers with diverse backgrounds but also promotes career advancement for women and URM.[Table: see text]
Collapse
Affiliation(s)
- Ivy Riano
- Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | | | | | - Angela Ai
- University of Wisconsin School of Medicine and Public Health, Madison, WI
| | - Gabriella Geiger
- University of Wisconsin School of Medicine and Public Health, Madison, WI
| | | | | | - Natasha Dhawan
- Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - Nazli Dizman
- City of Hope Comprehensive Cancer Center, Duarte, CA
| | | | - Narjust Duma
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
| |
Collapse
|
10
|
García LS, Riano I, Bravo LE, Collazos P, Holguín J. Enhancing Cancer Control Through a Population-Based Cancer Registry in Cali, Colombia: Results From 20-Year Cancer Survival Trends. JCO Glob Oncol 2022. [DOI: 10.1200/go.22.33000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Population-based survival is a strategic measure of the health system efficiency when managing cancer in a country. By analyzing data from a city in a middle-income country, we aimed to generate further hypotheses about cancer survival that may have a national impact on cancer control. METHODS Cancer cases were collected using the Population-Based Cancer Registry from Cali, Colombia, from 1998 to 2017. We examined the survival of nine cancers or groups of malignancies in patients aged 15-99 years old. The 5-year net survival (NS) was estimated using the Pohar-Perme method. Survival analyses were calculated using the life table method for each calendar year, single year of age, and sex. We used the cohort approach for patients diagnosed in 1998-2012 and the period approach during 2013-2017. RESULTS A total of 59,911 patients were available for analysis. The cancer types included n = 7,460 (12.5%) stomach, n = 6,760 (11.3%) colorectal, n = 6,760 (11.3%) lung, n = 5,164 (8.6%) breast, n = 11,755 (19.6%) cervix, n = 11,284 (18.8%) prostate, n = 4,054 (6.8%) thyroid, n = 2,076 (3.5%) myeloid neoplasia, and n = 6,735 (11.2%) lymphoma. For men, prostate cancer had the highest NS (79.9%-90.1%), whereas thyroid cancer (87.1%-95.7%) in women. Lung and stomach cancer had the lowest survival rate (< 25%) in both sexes. Myeloid neoplasia had the largest variation in survival (15.9%-52.7% for men; 12.5%-49.8% for women), followed by lymphoma (27.6%-55.4% for men; 37.3%-53.4% for women) and colorectal cancer (38.5%-54% for men; 37.1%-55.7% for women). Patients with cervix cancer experienced no change in survival (54.4%-53%) and breast cancer increased approximately 10% (70.8%-81.1%) but remained stable during the last decade. CONCLUSION Our results in survival trends provide insights into the main types of cancer and their burden to the health system. These data contribute to evidence for national cancer prevention policies and the monitoring of the Cancer Control Plan launched by the Colombian government.
Collapse
Affiliation(s)
- Luz Stella García
- Population-Based Cali Cancer Registry, Department of Pathology, Universidad del Valle, Cali, Colombia
| | - Ivy Riano
- Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | - Luis Eduardo Bravo
- Population-Based Cali Cancer Registry, Department of Pathology, Universidad del Valle, Cali, Colombia
| | - Paola Collazos
- Population-Based Cali Cancer Registry, Department of Pathology, Universidad del Valle, Cali, Colombia
| | | |
Collapse
|
11
|
Bernabe-Ramirez C, Velazquez AI, Olazagasti C, Decat Bergerot C, Bergerot PG, Corona Cruz J, Riano I, Adaniel C, Ramirez F, Anampa J, Cajina C, Mena E, Gracia E, Menendez A, Idrovo H, Bezares R, Castillo Fernandez OO, Duque L, Corrales-Rodríguez L, Ramos G, Kihn-Alarcón AJ, Schlam I, Bruno X, Umanzor G, Castro JL, Losco F, Ubillos L, Richardet E, Soto-Perez-de-Celis E, Duma N. HOLA COVID-19 Study: Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America. JCO Glob Oncol 2022; 8:e2100251. [PMID: 35245084 PMCID: PMC8920462 DOI: 10.1200/go.21.00251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Revised: 12/04/2021] [Accepted: 02/01/2022] [Indexed: 11/20/2022] Open
Abstract
PURPOSE The HOLA COVID-19 study sought to evaluate the impact of COVID-19 on oncology practices across Latin America (LATAM), challenges faced by physicians, and how practices and physicians adapted while delivering care to patients with cancer. METHODS This international cross-sectional study of oncology physicians in LATAM included a 43-item anonymous online survey to evaluate changes and adaptations to clinical practice. Multivariable logistic regression analyses were used to evaluate the association of caring for patients with COVID-19 and changes to clinical practice. RESULTS A total of 704 oncology physicians from 19 countries completed the survey. Among respondents, the most common specialty was general oncology (34%) and 56% of physicians had cared for patients with COVID-19. The majority of physicians (70%) noted a decrease in the number of new patients evaluated during the COVID-19 pandemic when compared with prepandemic, and 73% reported adopting the use of telemedicine in their practice. More than half (58%) of physicians reported making changes to the treatments that they offered to patients with cancer. In adjusted models, physicians who had cared for patients with COVID-19 had higher odds of changing the type of chemotherapy or treatments that they offered (adjusted odds ratio 1.81; 95% CI, 1.30 to 2.53) and of delaying chemotherapy start (adjusted odds ratio 2.05; 95% CI, 1.49 to 2.81). Physicians identified significant delays in access to radiation and surgical services, diagnostic tests, and supportive care. CONCLUSION The COVID-19 pandemic has significantly disrupted global cancer care. Although changes to health care delivery are a necessary response to this global crisis, our study highlights the significant disruption and changes to the treatment plans of patients with cancer in LATAM resulting from the COVID-19 health care crisis.
Collapse
Affiliation(s)
| | - Ana I. Velazquez
- Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA
- National Clinician Scholars Program, Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA
| | - Coral Olazagasti
- Sylvester Comprehensive Cancer Center at the University of Miami, Miami, ML
| | | | | | | | - Ivy Riano
- Hematology and Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH
| | | | | | - Jesus Anampa
- Montefiore Medical Center/Albert Einstein College of Medicine/Albert Einstein Cancer Center, Bronx, NY
| | - Carmen Cajina
- Universidad Nacional Autonoma de Nicaragua, Managua, Nicaragua
| | - Evelin Mena
- Instituto Nacional Del Cancer Rosa Emilia Sanchez Perez de Tavares (INCART), Santo Domingo, Dominican Republic
| | - Elias Gracia
- National Institute of Oncology and Radiobiology, Havana City, Cuba
| | | | | | | | | | - Liseth Duque
- Hospital Universitario Dr Jose Maria Vargas, Caracas, Venezuela
| | | | - Glenda Ramos
- SOLCA, Instituto Oncologico Nacional, Guayaquil, Ecuador
| | - Alba J. Kihn-Alarcón
- Research Department, Liga Nacional Contra el Cáncer & Instituto de Cancerología, Guatemala City, Guatemala
| | | | - Ximena Bruno
- Hematology Oncology Division, Department of Medicine, University of Pennsylvania, Philadelphia, PA
| | | | - Jenny Lissette Castro
- Department of Medical Oncology, Oncology Hospital, Salvadoran Institute of Social Security, Rosales National Hospital, San Salvador, El Salvador
| | - Federico Losco
- Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Argentina
| | | | | | - Enrique Soto-Perez-de-Celis
- Department of Geriatrics, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
| | - Narjust Duma
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
| |
Collapse
|
12
|
Riano I, Cristancho C, Treadwell T. Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer. J Investig Med High Impact Case Rep 2021; 8:2324709620914796. [PMID: 32207346 PMCID: PMC7093687 DOI: 10.1177/2324709620914796] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Stevens-Johnson syndrome (SJS) is a life-threating mucocutaneous reaction
predominantly induced by drugs. Targeted cancer therapies such as pembrolizumab,
which has been approved for the treatment of metastatic malignancy, can cause
severe skin toxicities, including SJS. They are rare and inconsistently
reported. In this article, we report the case of a 80-year-old woman with
metastatic non–small cell lung cancer who had a SJS-like eruption involving oral
mucosa after 15 weeks of exposure of pembrolizumab (6 doses) and 7 days after 1
dose of recombinant zoster vaccine. SJS is a rare blistering disorder with high
mortality rate and significant morbidity. Causes include drugs, herpes viruses,
and immunization. The timing of the eruption soon after the receipt of
recombinant zoster vaccine suggests a role of vaccination in our patient, yet
patients receiving cancer immunotherapy may develop late-onset skin toxicity.
Therefore, we recommend long-term monitoring for mucocutaneous reactions after
initiation of pembrolizumab. Further research is needed to characterize the
immunological pathogenesis and improve timely recognition and treatment
strategies.
Collapse
Affiliation(s)
- Ivy Riano
- MetroWest Medical Center, Framingham, MA, USA
| | | | - Thomas Treadwell
- MetroWest Medical Center, Framingham, MA, USA.,Boston University, Boston, MA, USA
| |
Collapse
|
13
|
Park R, Lopes L, Lee S, Riano I, Saeed A. The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. Future Oncol 2021; 17:4221-4231. [PMID: 34323124 DOI: 10.2217/fon-2021-0552] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aims: The authors present a systematic review/meta-analysis of the impact of BRAF mutations on prognosis and immune checkpoint inhibitor (ICI) response in deficient mismatch repair/microsatellite instability-high colorectal cancer. Methods: Hazard ratios for overall survival and odds ratios for objective response rate to ICIs were calculated in BRAF-mutated versus BRAF wild-type patients. Results: After screening, nine and three studies, respectively, were included for analysis of prognosis (analysis A) and ICI response (analysis B). Analysis A showed worse overall survival in BRAF-mutated compared with BRAF wild-type stage I-IV patients (hazard ratio: 1.57; 95% CI: 1.23-1.99), and analysis B showed no difference in objective response rate (odds ratio: 1.04; 95% CI: 0.48-2.25). Conclusion: BRAF mutations are associated with worse overall survival but not differential response to ICIs in deficient mismatch repair/microsatellite instability-high colorectal cancer.
Collapse
Affiliation(s)
- Robin Park
- MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA 01702, USA
| | - Laercio Lopes
- MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA 01702, USA
| | - Sunggon Lee
- Department of Medicine, Korea University, Seoul 02841, Korea
| | - Ivy Riano
- MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA 01702, USA
| | - Anwaar Saeed
- Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS 66205, USA
| |
Collapse
|
14
|
Riano I, Bravo P, Bravo LE, Garcia LS, Collazos P, Carrascal E. Incidence, Mortality, and Survival Trends of Primary CNS Tumors in Cali, Colombia, From 1962 to 2019. JCO Glob Oncol 2021; 6:1712-1720. [PMID: 33156716 PMCID: PMC7713581 DOI: 10.1200/go.20.00368] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
PURPOSE Global studies have shown varying trends of CNS tumors within geographic regions. In Colombia, the epidemiologic characteristics of CNS neoplasms are not well elucidated. We aimed to provide a summary of the descriptive epidemiology of primary CNS tumors among the urban population of Cali, Colombia. METHODS We conducted a time-trend study from 1962 to 2019 using the Population-Based Cali Cancer Registry. The age-standardized rates per 100,000 person-years were obtained by direct method using the world standard population. Results were stratified by sex, age group at diagnosis, and histologic subtype. We used Joinpoint regression analysis to detect trends and obtain annual percentage change (APC) with 95% CIs. We estimated 5-year net survival using the Pohar-Perme method. RESULTS During 1962 to 2016, 4,732 new cases of CNS tumors were reported. From 1985 to 2019, a total of 2,475 deaths from malignant CNS tumors were registered. A statistically significant increase in the trends of incidence (APC, 2.8; 95% CI, 2.1 to 3.5) and mortality (APC, 1.5; 95% CI, 1.1 to 2.0) rates was observed during the study. The most common malignant CNS tumor was glioblastoma (17.8% of all tumors), and the most frequent benign tumor was meningioma (17.2%). Malignancy was more common in males than in females. Unspecified malignant neoplasms represented 32% of all cases. The highest 5-year net survival was 31.4% during 2012 to 2016. CONCLUSION Our findings demonstrate an increasing burden of primary CNS tumors for the last 60 years, with a steady rate from the early 2010s. There was an improvement of 5-year net survival for the last decade. Males had higher mortality than did females. Additional efforts are needed to fully explore the geographic, environmental, and genetic contributors of CNS malignancies within the region.
Collapse
Affiliation(s)
- Ivy Riano
- Department of Internal Medicine, MetroWest Medical Center, Tufts University School of Medicine, Framingham, MA
| | - Pablo Bravo
- Population-Based Cali Cancer Registry, Department of Pathology, Universidad del Valle School of Medicine, Cali, Colombia
| | - Luis Eduardo Bravo
- Population-Based Cali Cancer Registry, Department of Pathology, Universidad del Valle School of Medicine, Cali, Colombia
| | - Luz Stella Garcia
- Population-Based Cali Cancer Registry, Department of Pathology, Universidad del Valle School of Medicine, Cali, Colombia
| | - Paola Collazos
- Population-Based Cali Cancer Registry, Department of Pathology, Universidad del Valle School of Medicine, Cali, Colombia
| | - Edwin Carrascal
- Population-Based Cali Cancer Registry, Department of Pathology, Universidad del Valle School of Medicine, Cali, Colombia
| |
Collapse
|
15
|
Riano I, Pomares-Millan H, Prasongdee K, Park R, Duma N. Internal medicine residents’ awareness on cancer survivorship care plan: A cross sectional study. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.e23011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e23011 Background: Survivorship care plans (SCPs) is recommended as a tool for communication between oncologists and primary care physicians. According to the Institute of Medicine, it is necessary to lead a cultural shift to provide SCPs to all cancer survivors to improve the transition from the oncology clinic to primary care practices. Studies suggest residency training curriculums for internal medicine (IM) are lacking education about cancer survivorship and SCPs. We aimed to assess the awareness of trainees toward SCPs. Methods: A survey was distributed to IM trainees in an outpatient setting. We stratified the descriptive analyses by program type (transitional [TY] and categorical [CT] trainees) and year of training. Differences in the proportions were tested appropriately. Analyses were conducted in R v3.6.2. Results: 37 trainees were interviewed; 32.4% were TY and 67.6% CT trainees. A 54% were PGY-1, 21.6% PGY-2, and 24.3% PGY-3. None of the trainees reported following a SCP for cancer-free patients nor to use SCP as a source to obtain cancer-related information. 78.3% and 92.6% reported that they were not taught during residency or medical school about SCPs, respectively. 84.8% informed that cancer-related information was inaccessible during the encounter with patients; sources cancer diagnosis and treatment information included: patients/family members (97.3%), outside records (83.8%), and oncology notes (86.5%). By program type, there was a statistically significant difference between TY v. CT groups (p = 0.017) regarding how often cancer-related issues were discussed with patients; the TY group mainly reported ‘Not at all’ whether CT were more likely to engage in discussion about cancer. Differences in the trainees’ comfort level answering patients concerns about cancer recurrence were observed between TY v. CT trainees but was not statistically significant (p = 0.864). Most common barriers to discuss cancer history and/or SCP were insufficient information from patients (83.8%), perceived inaccuracy from patients’ information (81.1%), unclear if patient has a SCP (81.1%), lack of SCP in medical record (75.7%), and trainees’ low medical knowledge about side effects of cancer therapies (70.3%). Conclusions: The awareness of cancer SCP among the IM trainees is limited, and many have not accessed or received training in SCPs. Efforts intended to facilitate SCP use and educate residents about cancer survivorship may be effective to increase the comfort level of trainees managing the growing number of survivors and improve transition from oncology to primary care clinics.[Table: see text]
Collapse
Affiliation(s)
- Ivy Riano
- MetroWest Medical Center, Framingham, MA
| | | | | | - Robin Park
- MetroWest Medical Center, Framingham, MA
| | | |
Collapse
|
16
|
Bernabe Ramirez C, Velazquez Manana AI, Olazagasti C, Bergerot CD, Soto Perez De Celis E, Corona-Cruz JF, Riano I, Adaniel C, Ramirez F, Anampa Mesias JDS, Cajina C, Mena E, Gracia E, Menendez AG, Idrobo H, Bezares R, Castillo Fernandez OO, Duque Duran L, Bergerot PG, Duma N. The HOLA COVID-19 study: Evaluating the impact of caring for patients with COVID-19 on cancer care delivery in Latin America. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.1537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1537 Background: The severe acute respiratory syndrome 2 (SARS-cov-2) virus causing COVID-19 has brought great challenges to global health services affecting cancer care delivery, outcomes, and increasing the burden in oncology providers (OP). Our study aimed to describe the challenges that OP faced while delivering cancer care in Latin America. Methods: We conducted an international cross-sectional study using an anonymous online survey in Spanish, Portuguese, and English. The questionnaire included 43 multiple choice questions. The sample was stratified by OP who have treated patients with COVID-19 versus those who have not treated patients with COVID-19. Data was analyzed with descriptive statistics and Chi-square tests. Results: A total of 704 OP from 20 Latin American countries completed the survey (77% of 913 who started the survey). Oncologists represented 46% of respondents, followed by 25% surgical-oncologists. Of the respondents, 56% treated patients with COVID-19. A significant proportion of OP reported newly adopting telemedicine during COVID-19 (14% vs 72%, p=0.001). More than half (58%) of OP reported making changes to the treatments they offered to patients with cancer. As shown in the table, caring for patients with COVID-19 significantly influenced practice patterns of OP. Access to specialty services and procedures was significantly reduced: 40% noted significantly decreased or no access to imaging, 20% significantly decreased or no access to biopsies, 65% reported delays in surgical oncology referrals, and 49% in radiation oncology referrals. A vast majority (82%) reported oncologic surgeries were delayed or cancelled, which was heightened among those treating patients with COVID-19 (87% vs 77%, p=0.001). Conclusions: The COVID-19 pandemic has significantly affected the way cancer care is delivered in globally. Although changes to healthcare delivery are necessary as a response to this global crisis, our study highlights the significant disruption and possible undertreatment of patients with cancer in Latin America that results from COVID-19.[Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | - Ivy Riano
- MetroWest Medical Center, Framingham, MA
| | | | | | | | - Carmen Cajina
- Universidad Nacional Autonoma de Nicaragua, Managua, Nicaragua
| | - Evelin Mena
- Instituto Nacional Del Cancer Rosa Emilia Sanchez Perez de Tavares (INCART), Santo Domingo, Dominican Republic
| | | | | | | | | | | | - Liseth Duque Duran
- Hospital Universitario Dr. Jose Maria Vargas, Caracas, Venezuela (Bolivarian Republic of)
| | | | | |
Collapse
|
17
|
Velazquez Manana AI, Bernabe Ramirez C, Olazagasti C, Bergerot PG, Soto Perez De Celis E, Corona-Cruz JF, Riano I, Adaniel C, Ramirez F, Anampa Mesias JDS, Cajina C, Mena E, Gracia E, Menendez AG, Bezares R, Castillo Fernandez OO, Duque Duran L, Corrales LA, Bergerot CD, Duma N. Impact of COVID-19 on work-related fatigue and satisfaction among oncology providers in Latin America: An analysis of the HOLA COVID-19 study. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.11014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11014 Background: The well-being of oncology providers (OP) is in jeopardy with increasing workload, limited resources, and personal challenges that result from the COVID-19 pandemic. We aim to evaluate the impact of COVID-19 on work-related (WR) satisfaction and fatigue among OP in Latin America. Methods: We conducted an international cross-sectional online survey of OP practicing in Latin America. The survey was administered in English, Spanish, and Portuguese. Data was analyzed using descriptive statistics and Chi-square tests. Results: In August 2020, 704 OP from 20 Latin American countries completed the survey (77% of 913 who started the survey). Table outlines baseline characteristics. Higher frequency of WR fatigue (67% vs. 58%, p=0.010) and exhaustion (81% vs. 70%, p=0.001) were reported by OP who cared for patients with COVID-19, compared to OP who cared for patients without COVID-19. Providers that observed delays in referrals to radiation (p=0.002) and surgery (p=0.04) reported WR fatigue at higher rates than their counterparts. Higher exhaustion (p=0.016) and dissatisfaction (p=0.046) were reported by OP who lacked access to supportive services, as social work. A significantly higher proportion of women reported WR fatigue (72% vs. 56%, p=0.003) and exhaustion (86% vs. 68%, p=0.001), when compared to men. Women were more likely than men to endorse higher current levels of fatigue when compared to pre-COVID-19 (61% vs. 46%, p=0.0001). To reduce stress, women were more likely than men to cut the time spent watching the news (p=0.002). Both genders declined research collaborations and speaking opportunities. Conclusions: Fatigue and dissatisfaction with work-life were prevalent among OP in Latin America. Higher rates of WR fatigue were seen in women, OP caring for patients with COVID-19, and OP with patients who experienced cancer care delays. Our data imply that OP may be a prime target for psychosocial support, particularly as current challenges will continue for the foreseen future. Baseline characteristics (N=704).[Table: see text]
Collapse
Affiliation(s)
| | | | | | | | | | | | - Ivy Riano
- MetroWest Medical Center, Framingham, MA
| | | | | | | | - Carmen Cajina
- Universidad Nacional Autonoma de Nicaragua, Managua, Nicaragua
| | - Evelin Mena
- Instituto Nacional Del Cancer Rosa Emilia Sanchez Perez de Tavares (INCART), Santo Domingo, Dominican Republic
| | | | | | | | | | - Liseth Duque Duran
- Hospital Universitario Dr. Jose Maria Vargas, Caracas, Venezuela (Bolivarian Republic of)
| | - Luis-Alberto Corrales
- Oncology Department, Hospital San Juan de Dios, San José Costa Rica, Costa Rica, San José, Costa Rica
| | | | | |
Collapse
|
18
|
Patel SR, Riano I, Geiger G, Pimienta J, Abuali I, Ai A, Ramirez Roggio A, Dhawan N, Dizman N, Salinas AL, Duma N. Where are the women and underrepresented minorities in medicine? Race/ethnicity and gender representation in oncology journals’ editorial boards. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.11007] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11007 Background: The proportion of women & underrepresented groups in medicine (URM) in the field of hematology and oncology remains low, particularly in academic leadership positions. Editorial board appointments allow physicians to have a substantial impact on the nature of the published scholarly work and serve as a platform for academic opportunities. We aimed to assess gender and race/ethnicity representation in editorial board positions in hematology and oncology journals. Methods: Editorial leadership board members from 60 journals from oncology, hematology, radiation oncology, and surgical oncology were reviewed, 54 journals were included in the analysis. Gender and race/ethnicity were determined based on publicly available data for editor-in-chief (EiC) and second-in-command (SiC) (including deputy, senior, or associate editors). Descriptive statistics and chi-squared were estimated. Results: A total of 793 editorial board members are included in the analysis. 72.6 % were men and 27.4 % were women. 71.3% of editorial leadership were non-Hispanic white with Asian editorial board members representing the second largest majority at 23.3%. The editorial position was significantly different among men and women (p = 0.038) with women filling only 15.9% (10/63) of the EiC positions. Of these 10 women, the racial breakdown was 90% white and 10% Asian. In the prevalence odds ratio (pOR), women were about half as likely to be in the EiC position compared with men [pOR: 0.47, 95%CI (0.23, 0.95, p = 0.03)]. Women represented 28.4% (207/730) of SiC editorial positions. White editors had the highest representation at 71.0% in the SiC editorial positions, followed by Asian editors at 16.0%. Notable differences were seen in gender proportions between journal specialties (p = 0.001); with surgical oncology and hematology having the lowest female representation at 11.9% and 22.7%, respectively. Conclusions: Women and UIM are markedly underrepresented in leadership roles on Editorial Boards in hematology and oncology journals. Importantly, the representation of minority women physicians in EiC positions is at an inexorable zero which is a sign of unconscious attitudes that may exclude women and minorities from certain positions. It is imperative that we work to move towards a more diverse and inclusive editorial board to ensure critical perspectives are heard and scientific discovery is fostered.[Table: see text]
Collapse
Affiliation(s)
| | - Ivy Riano
- MetroWest Medical Center, Framingham, MA
| | - Gabriella Geiger
- University of Wisconsin School of Medicine and Public Health, Madison, WI
| | | | - Inas Abuali
- University of Cincinnati Medical Center, Cincinnati, OH
| | - Angela Ai
- University of Wisconsin School of Medicine and Public Health, Madison, WI
| | | | | | - Nazli Dizman
- City of Hope Comprehensive Cancer Center, Duarte, CA
| | | | | |
Collapse
|
19
|
Riano I, Prasongdee K. A Rare Cause of Isolated Prolonged Activated Partial Thromboplastin Time: An Overview of Prekallikrein Deficiency and the Contact System. J Investig Med High Impact Case Rep 2021; 9:23247096211012187. [PMID: 33940978 PMCID: PMC8114252 DOI: 10.1177/23247096211012187] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Prekallikrein (PK) deficiency, also known as Fletcher factor deficiency, is a very rare disorder inherited as an autosomal recessive trait. It is usually identified incidentally in asymptomatic patients with a prolonged activated partial thromboplastin time (aPTT). In this article, we present the case of a 52-year-old woman, with no prior personal or family history of thrombotic or hemorrhagic disorders, who was noted to have substantial protracted aPTT through the routine coagulation assessment before a kidney biopsy. The patient had an uneventful biopsy course after receiving fresh frozen plasma (FFP). Laboratory investigations performed before the biopsy indicated normal activity for factors VIII, IX, XI, XII, and von Willebrand factor (vWF) as well as negative lupus anticoagulant (LA) screen. The plasma PK assay revealed low activity at 15% consistent with mild PK deficiency. The deficit of PK is characterized by a severely prolonged aPTT and normal prothrombin time (PT) in the absence of bleeding tendency. PK plays a role in the contact-activated coagulation pathway and the inflammatory response. Thus, other differential diagnoses of isolated prolonged aPTT include intrinsic pathway factor deficiencies and nonspecific inhibitors such as LA. We concluded that the initial evaluation of a prolonged aPTT with normal PT should appraise the measurement of contact activation factors and factor inhibitors. PK deficiency should be considered in asymptomatic patients with isolated aPTT prolongation, which corrects on incubation, with normal levels of the contact activation factors and factor inhibitors.
Collapse
Affiliation(s)
- Ivy Riano
- MetroWest Medical Center, Framingham, MA, USA.,Tufts University, Boston, MA, USA
| | - Klaorat Prasongdee
- MetroWest Medical Center, Framingham, MA, USA.,Tufts University, Boston, MA, USA
| |
Collapse
|
20
|
Park R, Lopes da Silva L, Nissaisorakarn V, Riano I, Williamson S, Sun W, Saeed A. Comparison of Efficacy of Systemic Therapies in Advanced Hepatocellular Carcinoma: Updated Systematic Review and Frequentist Network Meta-Analysis of Randomized Controlled Trials. J Hepatocell Carcinoma 2021; 8:145-154. [PMID: 33791250 PMCID: PMC7997949 DOI: 10.2147/jhc.s268305] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Accepted: 03/08/2021] [Indexed: 12/30/2022] Open
Abstract
Background Several systemic agents have been approved for use in advanced hepatocellular carcinoma (aHCC). However, it is unclear which treatment is superior in either the first- or second-line settings due to the paucity of head-to-head comparative trials. Therefore, we have conducted a systematic review and network meta-analysis for the indirect comparison of the systemic agents in the first line and second line settings. Methods Randomized clinical trials evaluating systemic agents in first and second line settings in aHCC from inception to April 2020 were identified by searching PubMed, EMBASE, and Cochrane Databases and the annual ASCO and ESMO conferences from 2017 to 2020. Studies in English reporting clinical outcomes including overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) were included. The primary outcomes of interest were pooled hazard ratios (HR) of OS and pooled odds ratios (OR) of ORR in first line studies and pooled HR of PFS and OR of ORR for second line studies. Additionally, OS for second line agents were reported in the qualitative analysis. Results Overall, first line studies comprised 8335 patients (13 studies) and second line studies comprised 4612 patients (11 studies). In the first line setting, atezolizumab plus bevacizumab was associated with the highest OS benefit over sorafenib (HR 0.58, 95% CI, 0.42-0.80; P-score 0.993). Additionally, lenvatinib was associated with the greatest ORR benefit (OR 3.34, 95% CI, 2.17-5.14; P-score 0.080) in the first line setting. In the second line setting, cabozantinib was associated with the highest PFS benefit over placebo (HR 0.44, 95% CI, 0.29-0.66; P-score 0.854) as well as the highest ORR benefit (OR 9.40, 95% CI, 1.25-70.83, P-score, 0.266). Conclusion Atezolizumab plus bevacizumab appears to have superior efficacy among first line agents whereas cabozantinib appears to be superior in the second line setting. Further studies are warranted to determine whether the type of prior therapy received affects the efficacy of subsequent second line therapy.
Collapse
Affiliation(s)
- Robin Park
- Department of Medicine, MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, USA
| | - Laercio Lopes da Silva
- Department of Medicine, MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, USA
| | - Voravech Nissaisorakarn
- Department of Medicine, MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, USA
| | - Ivy Riano
- Department of Medicine, MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, USA
| | - Stephen Williamson
- Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS, USA
| | - Weijing Sun
- Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS, USA
| | - Anwaar Saeed
- Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS, USA
| |
Collapse
|
21
|
Riano I, Milla-Godoy G, Conrad S, Treadwell T. A Curious Case of a Cardiac Mass: Tumor or Thrombus? Examining Clinical-Radiologic-Pathologic Correlation. Am J Med 2021; 134:e115-e116. [PMID: 32835689 DOI: 10.1016/j.amjmed.2020.07.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 07/06/2020] [Indexed: 10/23/2022]
Affiliation(s)
- Ivy Riano
- Department of Internal Medicine, MetroWest Medical Center, Framingham, Mass.
| | | | - Stephanie Conrad
- Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, Mass
| | - Thomas Treadwell
- Department of Internal Medicine, MetroWest Medical Center, Framingham, Mass; Section of Infectious Diseases, Department of Medicine, Boston Medical Center and Boston School of Medicine, Boston, Mass
| |
Collapse
|
22
|
Park R, Lopes da Silva L, Nissaisorakarn V, Riano I, Saeed A. Comparison of systemic therapy efficacy in advanced hepatocellular carcinoma: Systematic review and frequentist network meta-analysis of randomized controlled trials. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.3_suppl.293] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
293 Background: Several systemic agents are approved for use in the first line and second line treatment settings for advanced hepatocellular carcinoma (aHCC). However, choosing among available options in both first and second line settings remain difficult due to the paucity of head-to-head comparative trials. Therefore, we have conducted a systematic review and network meta-analysis for the indirect comparison of the systemic agents in the first line and second line settings. Methods: Published clinical trials that have evaluated systemic agents in the first line and second line settings in advanced HCC from inception to April 2020 were identified by searching PubMed, EMBASE, and Cochrane Databases and abstracts presented in the main annual ASCO and ESMO conferences from 2017 to 2020. Studies published in English providing clinical outcomes data including overall survival (OS), progression free survival (PFS) and objective response rate (ORR) were included in the analysis. The primary outcomes of interest were pooled hazard ratios (HR) of OS and OR of ORR in first line studies and HR of PFS and OR of ORR for second line studies. OS for second line agents were synthesized in a qualitative analysis. Results: Overall, 8,335 patients (13 studies) and 4,612 patients (11 studies) were analyzed in phase II/III trials for first line and second line settings respectively. In the first line setting, atezolizumab plus bevacizumab and lenvatinib were ranked highest as the regimens associated with the greatest OS (A+B, HR 0.58, 95% CI, 0.42-0.80; P-score 0.993) and ORR (lenva, OR 3.34, 95% CI, 2.17-5.14; P-score 0.080) respectively. In the second line setting, cabozantinib showed the highest probability of greatest PFS benefit (HR 0.44, 95% CI, 0.29-0.66; P-score 0.854) as well as the highest probability of greatest ORR benefit (cabo, OR 9.40, 95% CI, 1.25-70.83, P-score, 0.266). Conclusions: In the first line setting, atezolizumab plus bevacizumab may be the superior regimen whereas lenvatinib may be considered as the initial option when robust tumor responses are preferred. In the second line setting, cabozantinib may be the preferred option including in cases when robust tumor responses are favored.
Collapse
Affiliation(s)
- Robin Park
- MetroWest Medical Center, Framingham, MA
| | | | | | - Ivy Riano
- MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA
| | - Anwaar Saeed
- University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
23
|
Park R, Lopes da Silva L, Riano I, Cristancho C, Saeed A. Treatment-related adverse events of combination immune checkpoint inhibitors: Systematic review and meta-analysis. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.15_suppl.e15060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15060 Background: Despite increasing clinical experience with immune checkpoint inhibitors and the recent publication of clinical practice guidelines for managing treatment-related adverse events, precise and nuanced checkpoint inhibitor data in the setting of combination therapy is lacking. Herein we have conducted a systematic review and meta-analysis of treatment-related adverse event data from clinical trials evaluating combination immune checkpoint inhibitors. Methods: Studies published in PubMed, Embase, and Cochrane Database from conception to September 28, 2019 were included in the meta-analysis. Studies were eligible for inclusion if combination immune checkpoint inhibitor therapy was evaluated in advanced unresectable cancer and treatment-related adverse event data were available. For comparison of severity of adverse events in combination versus monotherapy, only the studies containing monotherapy arms as a control population were included, while all were included for calculation of pooled incidence of selected adverse events. Pooled risk ratio (RR) was used for the comparison of combination versus monotherapy and the logit transformed proportion for calculation of pooled incidence. Between-study risk of bias was evaluated using the Begg's funnel plot and Egger's regression test. Subgroup analysis was conducted by combination regimen, cancer type, and dosing regimen. Results: A total of 18 studies comprising 2767 patients across 10 cancer types were included in the final analysis. Combination ICI was associated with a slightly higher risk of all-grade adverse events (RR 1.07 [95% CI 1.03-1.11]) and markedly greater risk of grade 3 or higher adverse events (RR 2.21 [95% CI 1.57-3.10]) compared to monotherapy ICI. Subgroup analyses showed significant differences in risk of grade 3 or higher adverse events between treatment type (PD-1+CTLA-4 and PD-L1+CTLA-4), among cancer types, and among dosing regimens (N1I3, N3I1 and D20T1). Incidence of all-grade adverse events was 0.905 [95% CI 0.842-0.945] and grade 3 or higher events/all-grade adverse events was 0.396 [95% CI 0.315-0.483]. The most common all-grade TRAEs were diarrhea/colitis, fatigue/asthenia, nausea/vomiting, rash, and pruritis. Conclusions: Combination ICI therapy has a significantly different treatment-related adverse event profile compared to monotherapy.
Collapse
Affiliation(s)
- Robin Park
- MetroWest Medical Center, Framingham, MA
| | | | - Ivy Riano
- MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA
| | - Cagney Cristancho
- MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA
| | - Anwaar Saeed
- University of Kansas Medical Center, Kansas City, KS
| |
Collapse
|
24
|
Cristancho C, Riano I, Guareras-Paredes D, Park R, Seetharaman K. Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab. Cureus 2020; 12:e8072. [PMID: 32542127 PMCID: PMC7290116 DOI: 10.7759/cureus.8072] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Locally advanced cutaneous squamous cell carcinoma (cSCC) represents a challenge in treatment. Only very recently (February 2020) have guidelines been released regarding the management of unresectable, locally advanced cSCC. With the introduction of check point inhibitors during the last decade, anti-PD-1 antibodies represent a novel immunotherapeutic strategy in cancer. We present a case of an advanced cSCC not amenable to surgical resection, who experienced dramatic improvement following treatment with the programmed cell death protein 1 receptor (PD-1) inhibitor pembrolizumab as an immunotherapeutic strategy.
Collapse
Affiliation(s)
- Cagney Cristancho
- Internal Medicine, Metrowest Medical Center/Tufts University School of Medicine, Framingham, USA
| | - Ivy Riano
- Internal Medicine, Metrowest Medical Center/Tufts University School of Medicine, Framingham, USA
| | - Daniel Guareras-Paredes
- Internal Medicine, Metrowest Medical Center/Tufts University School of Medicine, Framingham, USA
| | - Robin Park
- Internal Medicine, Metrowest Medical Center/ Tufts University School of Medicine, Framingham, USA
| | | |
Collapse
|
25
|
Riano I, Paredes-Guarderas D, Mangano M. Gallbladder Metastasis From Cervical Human Papillomavirus-Related Squamous Cell Carcinoma Presenting as Acute Cholecystitis. JCO Oncol Pract 2020; 16:179-180. [PMID: 32048925 DOI: 10.1200/jop.19.00578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Ivy Riano
- Department of Internal Medicine, MetroWest Medical Center, Framingham, MA
| | | | - Mark Mangano
- Department of Pathology, Milford Regional Medical Center, Milford, MA
| |
Collapse
|
26
|
Llop S, Ibarluzea J, Riano I, Sunyer J, Ballester F. The Authors Reply. Am J Epidemiol 2012. [DOI: 10.1093/aje/kws388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|